Cargando…

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

SUMMARY: Romosozumab is a therapy that stimulates bone formation and reduces bone resorption. In this study of postmenopausal women with low BMD, a second course of romosozumab following a period off treatment or on denosumab increased or maintained BMD, respectively, and was well tolerated, providi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kendler, D.L., Bone, H.G., Massari, F., Gielen, E., Palacios, S., Maddox, J., Yan, C., Yue, S., Dinavahi, R.V., Libanati, C., Grauer, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877701/ https://www.ncbi.nlm.nih.gov/pubmed/31628490 http://dx.doi.org/10.1007/s00198-019-05146-9

Ejemplares similares

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension
por: Miyauchi, Akimitsu, et al.
Publicado: (2019)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab
por: McClung, M. R., et al.
Publicado: (2020)

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
por: Hu, Mingwei, et al.
Publicado: (2023)

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
por: Schemitsch, Emil H., et al.
Publicado: (2020)

Romosozumab and antiresorptive treatment: the importance of treatment sequence
por: Cosman, Felicia, et al.
Publicado: (2022)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
por: Langdahl, Bente, et al.
Publicado: (2022)

Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
por: Baek, Ki-Hyun, et al.
Publicado: (2021)

Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study
por: Lau, E. M. C., et al.
Publicado: (2020)

Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
por: Cosman, Felicia, et al.
Publicado: (2021)

Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
por: Shimizu, Tomohiro, et al.
Publicado: (2021)

Two Cases of Frontal Variation of Idiopathic Calvarial Thinning—Therapeutic Effect of Denosumab and Romosozumab
por: Baek, Seungjin, et al.
Publicado: (2023)

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
por: Austin, Matthew, et al.
Publicado: (2012)

Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density
por: Poole, Kenneth ES, et al.
Publicado: (2021)

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study
por: Geusens, Piet, et al.
Publicado: (2019)

Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
por: Chavassieux, Pascale, et al.
Publicado: (2019)

Romosozumab for osteoporosis
Publicado: (2021)

Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report
por: Kashii, Masafumi, et al.
Publicado: (2020)

Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019)

Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study
por: Mochizuki, Takeshi, et al.
Publicado: (2021)

T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
por: Cosman, Felicia, et al.
Publicado: (2020)

Romosozumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2018)

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
por: Ferrari, S., et al.
Publicado: (2015)

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
por: Watts, N. B., et al.
Publicado: (2011)

Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab
por: Hsu, Cheng‐Pang, et al.
Publicado: (2022)

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
por: Papapoulos, S., et al.
Publicado: (2015)

Romosozumab and cardiovascular safety in Japan
por: Takeuchi, Yasuhiro
Publicado: (2021)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
por: Ferrari, S, et al.
Publicado: (2019)

A Pooled Analysis of Fall Incidence From Placebo‐Controlled Trials of Denosumab
por: Chotiyarnwong, Pojchong, et al.
Publicado: (2020)

Discontinuation of Denosumab: Gradual Decrease in Doses Preserves Half of the Bone Mineral Density Gain at the Lumbar Spine
por: Laroche, Michel, et al.
Publicado: (2023)

Romosozumab in osteoporosis: yesterday, today and tomorrow
por: Wu, Dong, et al.
Publicado: (2023)

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
por: Keaveny, Tony M, et al.
Publicado: (2014)

OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
por: Feldman, Robert, et al.
Publicado: (2020)

Profile of romosozumab and its potential in the management of osteoporosis
por: Lim, Sian Yik, et al.
Publicado: (2017)

Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study
por: Inose, Hiroyuki, et al.
Publicado: (2022)

Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease
por: Miller, Paul D, et al.
Publicado: (2022)

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial
por: Brown, Jacques P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h69iai030lljn7loriktk161nr